EP3461503

BIOMARIN PHARMACEUTICAL INC.
Application Number
EP18205446A
Filing Date
Apr 11, 2008
Status
Revoked
Jun 14, 2024
Grant Date
May 11, 2022
External Links
Slate, Register

Biblio Summary

The patent EP3461503B9 was granted on May 11, 2022 by Biomarin Pharmaceutical Inc. The patent is currently Revoked.

The table below shows 5 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

CORIPHARMA EHF.Nov 9, 2022ADMISSIBLE
DIPHARMA S.A.Nov 9, 2022WITHDRAWN
BETAPHARM ARZNEIMITTEL GMBHOct 28, 2022ADMISSIBLE
SANDOZOct 12, 2022ADMISSIBLE
STADAOct 5, 2022ADMISSIBLE

The table below shows the patents of Biomarin Pharmaceutical Inc. that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3138566Treatment Of Phenylketonuria With Bh4Jan 26, 20223
EP3175863Variants Of C-Type Natriuretic PeptideDec 1, 20211
EP2545939Methods Of Administering Tetrahydrobiopterin, Associated Compositions, And Methods Of MeasuringDec 16, 20205

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.